GlassScriptPhysician profile
James Schmidt
NPI 1043667652
$5,260.14
in general payments reported to CMS, 2019-2025
29 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $327 · 2021: $487 · 2022: $558 · 2023: $2,086 · 2024: $1,423 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,450 · Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,450.00 |
| Food and Beverage | $1,192.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Solutions INC | $2,543.56 | 2022-2024 | |
| Amgen INC. | $867.58 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Medtronic, INC. | $276.32 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Horizon Therapeutics Plc | $202.05 | 2021-2023 | Krystexxa |
| Anika Therapeutics, INC. | $198.46 | 2021-2023 | Tactoset, Integrity |
| Abbvie INC. | $187.00 | 2019-2022 | |
| Argentum Medical | $137.62 | 2023 | |
| Medtronic Vascular, INC. | $114.80 | 2019 | |
| Lilly USA, LLC | $102.24 | 2022-2023 | Taltz |
| Mallinckrodt Hospital Products INC. | $93.84 | 2020-2021 | |
| Sanara Medtech INC. | $77.63 | 2024 | Celleraterx |
| Janssen Biotech, INC. | $66.12 | 2022-2023 | Tremfya |
| Alexion Pharmaceuticals, INC. | $43.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.14 | 2020 | |
| Abbott Laboratories | $39.53 | 2024-2025 | Aveir, Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $37.96 | 2019 | |
| Averitas Pharma INC. | $25.98 | 2025 | Qutenza |
| Smith+Nephew, INC. | $24.21 | 2024 | Grafix |
| Medartis INC. | $23.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.94 | 2022 | |
| Impulse Dynamics (USA) INC. | $20.05 | 2024 | Optimizer |
| Glaxosmithkline, LLC. | $19.19 | 2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $17.89 | 2021 | |
| Orthofix Medical, INC. | $16.82 | 2025 | Physio-Stim |
| Mallinckrodt Enterprises LLC | $14.99 | 2019 | |
| Organon LLC | $14.27 | 2023 | Hadlima, Renflexis |
| Teva Pharmaceuticals USA, INC. | $12.90 | 2023 | Truxima |
| Hikma Pharmaceuticals USA | $12.50 | 2020 | |
| Advanced Oxygen Therapy INC. | $6.64 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.